Family burden of hospital-managed pediatric atopic dermatitis: A nationwide registry-based study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Accepteret manuskript, 8,77 MB, PDF-dokument
Background: Parents of children with atopic dermatitis (AD) report reduced quality of life and higher stress level, which could increase risk of psychiatric and pain disorders, and medication use. Methods: By use of Danish national registries, we identified family members of all first-born Danish children born between 1 January 1995 and 31 December 2013 with a hospital diagnosis of AD, matched them 1:10 with family members of children without AD, and followed the cohorts over time. Results: Mothers of children with hospital-managed AD had higher risk of filling a prescription for medications for depression, anxiety, pain and sleep problems, and of consulting a psychologist, but most associations disappeared after full adjustment. Siblings had higher risk of receiving a diagnosis for adjustment disorder, and fathers showed increased risk of filling a prescription for pain medication and of divorce, in crude but not adjusted models. Conclusions: The increased risk of study endpoints seen in mothers of children with hospital-managed AD was not explained by pediatric AD alone. Rather, the total burden in these families including parent and child morbidity and socioeconomic resources seems to explain these observations. The burden in families of children with AD may potentially affect the overall management of their child's AD.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | e13693 |
| Tidsskrift | Pediatric Allergy and Immunology |
| Vol/bind | 33 |
| Udgave nummer | 1 |
| ISSN | 0905-6157 |
| DOI | |
| Status | Udgivet - jan. 2022 |
Bibliografisk note
Funding Information:
Dr. Vittrup has received salary from funding associated with this study from Sanofi and Regeneron Pharmaceuticals, Inc. Dr. Andersen has received research funding from AP Møller Foundation and the Kgl Hofbundtmager Aage Bang Foundation. Dr. Droitcourt has received honoraria from Sanofi‐Genzyme. Dr. Skov has been a paid speaker for AbbVie, Eli Lilly, Novartis, and LEO Pharma, and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall, and Sanofi. She has served as an investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZenica, Eli Lilly, Novartis, Regeneron, and LEO Pharma, and has received research and educational grants from Novartis, Sanofi, Janssen Cilag, and LEO Pharma. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, Bristol‐Myers Squibb, Mylan, UCB, and Janssen Pharmaceuticals. Dr. Thyssen has attended advisory boards for Sanofi‐Genzyme, Regeneron, LEO Pharma, Union Therapeutics, Pfizer, AbbVie and Eli Lilly & Co., and received speaker honorarium from LEO Pharma, Regeneron, AbbVie, and Sanofi‐Genzyme, and been an investigator for Sanofi‐Genzyme, Eli Lilly & Co., LEO Pharma, Pfizer, and AbbVie. Mr Delevry is an employee of and stockholder in Regeneron Pharmaceuticals Inc. Dr Fenton was previously an employee of and stockholder in Sanofi.
Funding Information:
The study was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
Publisher Copyright:
© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 305692365